Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A novel treatment for leukemias and lymphomas that arise from immune system T cells,  developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login